COVID-19 was not associated with cognitive impairment in the first year after infection among middle-aged individuals.

Shares in UCB slid this morning after the Belgian company announced its refractory epilepsy drug candidate padsevonil had failed a phase 2b trial. The ARISE trial of padsevonil did not reach ...

When SK Life Science began, it tapped into healthcare providers, patients, and scientists to ensure it was relentlessly focused on medical solutions to help drive success in treating central nervous ...